Objective: To investigate the clinical efficacy of adjusted Liujunzi Decoction combined with radiotherapy in the treatment of postoperative patients with spleen and stomach deficiency breast cancer.Methods: Randomly divided 78 patients with spleen-stomach-deficiency breast cancer into treatment group(n=39)and control group(n=39).Both groups received radiotherapy during the treatment.The treatment group also took Liujunzi decoction at the same time as radiotherapy in 6 weeks’ observation.Statistical methods were used to evaluate changes in TCM syndrome scores,tumor markers,Karsch scores,and toxicity after radiotherapy.Result:1.In the TCM syndrome scores,the treatment group was better than the control group in the relief of bloating,poor appetite,fatigue,loose stools,pale complexion,thin body,and suffocation.And the difference was statistically significant(P<0.05).2.In terms of the efficacy of tumor markers,the level of tumor markers in the treatment group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).3.As for the Karsch score,the Karst scores of the two groups were improved after treatment,and the increase of the treatment group was higher than that of the control group,the difference was statistically significant(P<0.05).4.In the follow-up results,the two groups were reviewed at the 6th and12 th months after the end of treatment.The number of relapses in the two groups was less,but the number of relapses and recurrence rate in the treatment group was lower than that in the control group.Conclusion:1.Adjusted Liujunzi Decoction combined with radiotherapy can reduce the tumor markers of patients with spleen and stomach weak breast cancer to a certain extent.2.Adjusted Liujunzi Decoction combined with radiotherapy can alleviate the clinical symptoms of patients with spleen and stomach deficiency breast cancer,improve patients’ KPS score and improve their quality of life.3.Adjusted Liujunzi Decoction combined with radiotherapy can have a certain effect on the long-term recurrence rate of patients with spleen-stomach deficiency breast cancer. |